Valuation: SCYNEXIS, Inc.

Market Cap 39.3M 35.2M 32.48M 29.39M 54.95M 3.74B 55.84M 387M 155M 1.96B 147M 144M 6.2B P/E 2026 *
-1.36x
P/E 2027 * -1.71x
Enterprise Value 39.3M 35.2M 32.48M 29.39M 54.95M 3.74B 55.84M 387M 155M 1.96B 147M 144M 6.2B EV / Sales 2026 *
63.4x
EV / Sales 2027 * 5.89x
Free-Float
97.95%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-3.67%
1 week-0.13%
Current month-22.98%
1 month-18.35%
3 months+0.93%
6 months-49.09%
Current year-24.79%
1 week 3.66
Extreme 3.6601
4.04
1 month 3.54
Extreme 3.535
5.51
Current year 3.53
Extreme 3.53
9.12
1 year 3.53
Extreme 3.53
9.12
3 years 3.53
Extreme 3.53
24.56
5 years 3.53
Extreme 3.53
64.8
10 years 3.53
Extreme 3.53
323.2
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 50 09/09/2026
Chief Tech/Sci/R&D Officer - 14/09/2026
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 A Free

Director

11,500 0.1156%
9/9/26 A Free

Chief Financial Officer

100,000 1.0051%
4/1/26 A Buy

Chief Executive Officer

217,390 0.2736%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%-0.13%-30.76%-72.51% 39.3M
+5.91%+4.80%+68.33%+142.08% 1,148B
+1.09%+2.62%+47.17%+86.78% 652B
+0.91%+1.11%+28.08%+103.22% 505B
+0.73%+2.45%+54.26%+66.47% 384B
+4.49%+0.43%+70.79%+44.01% 348B
+2.38%+2.65%+34.31%+56.33% 294B
+2.26%+0.55%+3.92%+27.74% 264B
+1.31%+2.45%+57.06%+74.12% 244B
+1.30%+2.39%+35.82%+106.96% 197B
Average +1.68%+1.68%+36.90%+63.52% 403.72B
Weighted average by Cap. +2.91%+1.50%+49.79%+93.10%

Financials

2026 *2027 *
Net sales 620K 555K 512K 463K 866K 58.99M 880K 6.11M 2.44M 30.87M 2.32M 2.28M 97.79M 6.68M 5.98M 5.52M 4.99M 9.34M 636M 9.49M 65.83M 26.26M 333M 25.06M 24.53M 1.05B
Net income -30.55M -27.36M -25.24M -22.84M -42.72M -2.91B -43.41M -301M -120M -1.52B -115M -112M -4.82B -32.43M -29.05M -26.8M -24.25M -45.35M -3.09B -46.08M -320M -128M -1.62B -122M -119M -5.12B
Net Debt - -
Projected Income Statement - Annual - SCYNEXIS, Inc.
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
29/10/26 $3.805 -3.67% 116,384
28/10/26 $3.950 +3.95% 53,872
27/10/26 $3.800 -0.26% 43,178
26/10/26 $3.810 +0.66% 64,010
23/10/26 $3.785 -0.66% 54,998
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - SCYNEXIS, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.950USD
Average target price
36.33USD
Spread / Average Target
+819.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SCYNEXIS, Inc.
  1. Stock Market
  2. Stocks
  3. SCYX Stock